Journal article
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, A Gleave, S Yip, A Angeles, S Hotte, B Tran, S North, S Taavitsainen, K Beja, G Vandekerkhove, E Ritch, E Warner, F Saad, N Iqbal Show all
European Urology | Published : 2020
Abstract
Somatic mutations that activate phosphatidylinositol 3-kinase pathway members AKT1 and PIK3CA define a distinct subclass of metastatic prostate cancer, and are sufficiently common to warrant biomarker-driven clinical trials. Mutation clonal prevalence and allelic imbalance may further aid patient stratification.
Grants
Awarded by Amgen
Funding Acknowledgements
This work was supported by research grants from the Canadian Institutes of Health Research (CIHR; Kim N. Chi and Alexander W. Wyatt), Prostate Cancer Foundation (Kim N. Chi and Alexander W. Wyatt), Prostate Cancer Canada (Kim N. Chi and Alexander W. Wyatt), the Jane and Aatos Erkko Foundation (Matti Annala), and a Terry Fox New Frontiers Program Project grant (#TFF116129; Kim N. Chi, Martin E. Gleave, and Alexander W. Wyatt). The sponsors played no direct role in the study. All targeted sequencing data are available at the European Genome-phenome Archive (accession number EGAS00001004328).